title: Sentinel lymph node biopsy in patients with previous ipsilateral complete axillary lymph node dissection.
abstract: BACKGROUND
  Prior ipsilateral completion axillary lymph node dissection (CALND) may be considered a contraindication to performing a sentinel lymph node (SLN) mapping in a patient with recurrent breast carcinoma. However, reoperative SLN biopsy following axillary dissection would determine if alternative lymphatic drainage pathways exist. If nodes were found to contain metastatic disease, staging and locoregional control of the disease could be affected.
  
  
  METHODS
  An institutional breast cancer database and electronic health record (IRB No. 102554) prospectively accrued 6225 patients between 1994 and 2007. Under separate IRB approval (IRB No. 102552), this database was queried for patients with a prior history of CALND who received a SLN biopsy. Patients' demographic, clinical, and treatment variables were recorded.
  
  
  RESULTS
  Of the 6225 patients, 45 (0.7%) were identified as having previously undergone breast-conservation surgery, CALND, and ipsilateral reoperative SLN mapping and biopsy. Of the 45 patients, 13 (29%) had a successful ipsilateral reoperative SLN mapping and biopsy. Nonaxillary drainage was identified in 5 patients with reoperative SLN biopsy.
  
  
  CONCLUSIONS
  Reoperative SLN mapping and biopsy is feasible in the setting of local recurrence after previous CALND. This procedure performed for breast cancer recurrence provides important staging information while identifying extra-axillary drainage that could affect both staging and local control.
authors.affiliation: H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL, USA.
authors.forename: Paramjeet
authors.initials: P
authors.lastname: Kaur
authors.forename: John V
authors.initials: JV
authors.lastname: Kiluk
authors.forename: Tammi
authors.initials: T
authors.lastname: Meade
authors.forename: Daniel
authors.initials: D
authors.lastname: Ramos
authors.forename: William
authors.initials: W
authors.lastname: Koeppel
authors.forename: Julia
authors.initials: J
authors.lastname: Jara
authors.forename: Jeff
authors.initials: J
authors.lastname: King
authors.forename: Charles E
authors.initials: CE
authors.lastname: Cox
mesh_terms: D002288:Adenocarcinoma, Mucinous / Q000556:secondary / Q000601:surgery*; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D001365:Axilla; D001943:Breast Neoplasms / Q000473:pathology / Q000601:surgery*; D018270:Carcinoma, Ductal, Breast / Q000556:secondary / Q000601:surgery*; D002285:Carcinoma, Intraductal, Noninfiltrating / Q000556:secondary / Q000601:surgery*; D018275:Carcinoma, Lobular / Q000556:secondary / Q000601:surgery*; D005260:Female; D006801:Humans; D008197:Lymph Node Excision; D008207:Lymphatic Metastasis; D008875:Middle Aged; D009361:Neoplasm Invasiveness; D009364:Neoplasm Recurrence, Local / Q000473:pathology / Q000601:surgery*; D011446:Prospective Studies; D021701:Sentinel Lymph Node Biopsy; D015996:Survival Rate; D016896:Treatment Outcome